Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 25.4% in April

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 340,300 shares, a decrease of 25.4% from the March 31st total of 455,900 shares. Based on an average daily trading volume, of 338,600 shares, the short-interest ratio is currently 1.0 days. Currently, 0.7% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Cellectis from a "hold" rating to a "buy" rating in a research note on Friday, April 25th.

Cellectis Stock Performance

Cellectis stock traded down $0.02 on Friday, hitting $1.59. The company's stock had a trading volume of 67,524 shares, compared to its average volume of 144,860. Cellectis has a one year low of $1.10 and a one year high of $3.38. The firm has a market cap of $88.43 million, a P/E ratio of -1.22 and a beta of 3.11. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a fifty day moving average price of $1.34 and a 200-day moving average price of $1.61.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). The business had revenue of $33.22 million during the quarter, compared to the consensus estimate of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. On average, equities analysts anticipate that Cellectis will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 12,500 shares in the last quarter. Millennium Management LLC bought a new position in shares of Cellectis in the 4th quarter worth $962,000. Finally, B Group Inc. bought a new position in Cellectis during the fourth quarter worth about $5,547,000. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.